Lawrence Fong MD

Oncology•Seattle, WA

Professor, Oncology, Fred Hutchinson Cancer Center

Join to View Full Profile

825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-520-5000

Summary

Lawrence Fong, MD is an Oncologist based in Seattle, WA. He completed ellowship from Stanford and a residency from the University of Washington. He currently serves as a Professor at Fred Hutchinson Cancer Center. He boasts an experience in cancer immunotherapy, and has featured in numerous academic publications, specifically investigating immune checkpoint inhibitor and developing new therapeutics for cancer. Dr. Fong founded and led the Cancer Immunotherapy Program at UCSF that performs clinical trials with immunotherapy, prior to moving to the Fred Hutch Cancer Center to lead the Integrated Immunotherapy Research Center. He was recognized for his prowess in healthcare with the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2012-2013.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1998
University of WashingtonResidency, Internal Medicine, 1991 - 1994
Stanford University School of MedicineClass of 1992

Certifications & Licensure

WA State Medical License 2024 - 2026
CA State Medical License 1994 - 2025
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer Start of enrollment: 2006 Jul 01
Completed
Phase 1
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer Start of enrollment: 2011 May 23
Completed
Phase 2
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer Start of enrollment: 2015 Jun 01
Withdrawn
Phase 2
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer Start of enrollment: 2014 Apr 22
Completed
Phase 2
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 1
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2013 Sep 10
Completed
Phase 2
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2014 Sep 02
Terminated
Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Start of enrollment: 2019 Oct 30
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
Ronald de Wit, David J Vaughn, Yves Fradet, Lawrence Fong, Miguel A Climent
European Urology. 2025-11-01
Expression of programmed death ligand-1 and programmed cell death-1 across the anal neoplasia disease continuum and association with survival in anal cancer.
Sona Chowdhury, Cynthia Gasper, Ann A Lazar, Kathryn Allaire, Teresa M Darragh
Modern Pathology. 2025-10-15
Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases.
Bridget P Keenan, Guilin Qiao, Nicholas Kunda, Lyonell Kone, Sophia M Guldberg
Science Advances. 2025-10-10

Press Mentions

Early-Career Physician-Scientists Receive Major Support from Damon Runyon Cancer Research FoundationJuly 13th, 2025
Researchers Have Brought the Promise of Stem Cell Therapies Closer to RealityNovember 24th, 2024
Overcoming the Challenges of Applying CAR T-cell Therapy to Solid TumorsNovember 8th, 2024
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member